These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 17211591)

  • 1. Effects of standard chemotherapy on tumor growth and regulation of multidrug resistance genes and proteins in childhood rhabdomyosarcoma.
    Seitz G; Warmann SW; Vokuhl CO; Heitmann H; Treuner C; Leuschner I; Fuchs J
    Pediatr Surg Int; 2007 May; 23(5):431-9. PubMed ID: 17211591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of glutathione-S-transferase as a treatment strategy for multidrug resistance in childhood rhabdomyosarcoma.
    Seitz G; Bonin M; Fuchs J; Poths S; Ruck P; Warmann SW; Armeanu-Ebinger S
    Int J Oncol; 2010 Feb; 36(2):491-500. PubMed ID: 20043085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sulforaphane induces apoptosis in rhabdomyosarcoma and restores TRAIL-sensitivity in the aggressive alveolar subtype leading to tumor elimination in mice.
    Bergantin E; Quarta C; Nanni C; Fanti S; Pession A; Cantelli-Forti G; Tonelli R; Hrelia P
    Cancer Biol Ther; 2014 Sep; 15(9):1219-25. PubMed ID: 24971463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical rationale for entinostat in embryonal rhabdomyosarcoma.
    Bharathy N; Berlow NE; Wang E; Abraham J; Settelmeyer TP; Hooper JE; Svalina MN; Bajwa Z; Goros MW; Hernandez BS; Wolff JE; Pal R; Davies AM; Ashok A; Bushby D; Mancini M; Noakes C; Goodwin NC; Ordentlich P; Keck J; Hawkins DS; Rudzinski ER; Mansoor A; Perkins TJ; Vakoc CR; Michalek JE; Keller C
    Skelet Muscle; 2019 May; 9(1):12. PubMed ID: 31113472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different expression profiles of Y-box-binding protein-1 and multidrug resistance-associated proteins between alveolar and embryonal rhabdomyosarcoma.
    Oda Y; Kohashi K; Yamamoto H; Tamiya S; Kohno K; Kuwano M; Iwamoto Y; Tajiri T; Taguchi T; Tsuneyoshi M
    Cancer Sci; 2008 Apr; 99(4):726-32. PubMed ID: 18377424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GLI inhibitor GANT-61 diminishes embryonal and alveolar rhabdomyosarcoma growth by inhibiting Shh/AKT-mTOR axis.
    Srivastava RK; Kaylani SZ; Edrees N; Li C; Talwelkar SS; Xu J; Palle K; Pressey JG; Athar M
    Oncotarget; 2014 Dec; 5(23):12151-65. PubMed ID: 25432075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multidrug resistance phenotype in the RMS-GR human rhabdomyosarcoma cell line obtained after polychemotherapy.
    Prados J; Melguizo C; Marchal JA; Vélez C; Alvarez L; Aránega A
    Jpn J Cancer Res; 1999 Jul; 90(7):788-93. PubMed ID: 10470293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological inhibition of EZH2 as a promising differentiation therapy in embryonal RMS.
    Ciarapica R; Carcarino E; Adesso L; De Salvo M; Bracaglia G; Leoncini PP; Dall'agnese A; Verginelli F; Milano GM; Boldrini R; Inserra A; Stifani S; Screpanti I; Marquez VE; Valente S; Mai A; Puri PL; Locatelli F; Palacios D; Rota R
    BMC Cancer; 2014 Feb; 14():139. PubMed ID: 24575771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mixed embryonal/alveolar rhabdomyosarcoma of the prostate: report of a case with molecular genetic studies and literature review.
    Treetipsatit J; Kittikowit W; Zielenska M; Chaipipat M; Thorner PS; Shuangshoti S
    Pediatr Dev Pathol; 2009; 12(5):383-9. PubMed ID: 19175284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Rhabdomyosarcoma in middle to old-aged patients: analysis of clinicopathological features and prognosis in 76 cases].
    Yu L; Wang J
    Zhonghua Zhong Liu Za Zhi; 2012 Dec; 34(12):910-6. PubMed ID: 23336377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term results from the multicentric European randomized phase 3 trial CWS/RMS-96 for localized high-risk soft tissue sarcoma in children, adolescents, and young adults.
    Sparber-Sauer M; Ferrari A; Kosztyla D; Ladenstein R; Cecchetto G; Kazanowska B; Scarzello G; Ljungman G; Milano GM; Niggli F; Alaggio R; Vokuhl C; Casanova M; Klingebiel T; Zin A; Koscielniak E; Bisogno G
    Pediatr Blood Cancer; 2022 Sep; 69(9):e29691. PubMed ID: 35441463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression and genomic status of EGFR and ErbB-2 in alveolar and embryonal rhabdomyosarcoma.
    Ganti R; Skapek SX; Zhang J; Fuller CE; Wu J; Billups CA; Breitfeld PP; Dalton JD; Meyer WH; Khoury JD
    Mod Pathol; 2006 Sep; 19(9):1213-20. PubMed ID: 16729016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumour expressions of hypoxic markers predict the response to neo-adjuvant chemotherapy in children with inoperable rhabdomyosarcoma.
    Krawczyk MA; Styczewska M; Sokolewicz EM; Kunc M; Gabrych A; Fatyga A; Izycka-Swieszewska E; Kazanowska B; Adamkiewicz-Drozynska E; Bien E
    Biomarkers; 2019 Sep; 24(6):538-548. PubMed ID: 30995126
    [No Abstract]   [Full Text] [Related]  

  • 14. MI-63: a novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53.
    Canner JA; Sobo M; Ball S; Hutzen B; DeAngelis S; Willis W; Studebaker AW; Ding K; Wang S; Yang D; Lin J
    Br J Cancer; 2009 Sep; 101(5):774-81. PubMed ID: 19707204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cetuximab promotes immunotoxicity against rhabdomyosarcoma in vitro.
    Herrmann D; Seitz G; Warmann SW; Bonin M; Fuchs J; Armeanu-Ebinger S
    J Immunother; 2010 Apr; 33(3):279-86. PubMed ID: 20445348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histology-specific expression of a DNA repair protein in pediatric rhabdomyosarcomas.
    Thomson B; Tritt R; Davis M; Kelley MR
    J Pediatr Hematol Oncol; 2001 May; 23(4):234-9. PubMed ID: 11846302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alveolar rhabdomyosarcoma: a prognostically unfavorable rhabdomyosarcoma type and its necessary distinction from embryonal rhabdomyosarcoma.
    Harms D
    Curr Top Pathol; 1995; 89():273-96. PubMed ID: 7882714
    [No Abstract]   [Full Text] [Related]  

  • 18. Significance of fusion status, Oberlin risk factors, local and maintenance treatment in pediatric and adolescent patients with metastatic rhabdomyosarcoma: Data of the European Soft Tissue Sarcoma Registry SoTiSaR.
    Heinz AT; Schönstein A; Ebinger M; Fuchs J; Timmermann B; Seitz G; Vokuhl C; Münter M; Pajtler KW; Stegmaier S; von Kalle T; Kratz CP; Ljungman G; Juntti H; Klingebiel T; Koscielniak E; Sparber-Sauer M;
    Pediatr Blood Cancer; 2024 Jan; 71(1):e30707. PubMed ID: 37814424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyper-activation of Notch3 amplifies the proliferative potential of rhabdomyosarcoma cells.
    De Salvo M; Raimondi L; Vella S; Adesso L; Ciarapica R; Verginelli F; Pannuti A; Citti A; Boldrini R; Milano GM; Cacchione A; Ferrari A; Collini P; Rosolen A; Bisogno G; Alaggio R; Inserra A; Locatelli M; Stifani S; Screpanti I; Miele L; Locatelli F; Rota R
    PLoS One; 2014; 9(5):e96238. PubMed ID: 24797362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic effect of bromocriptine and tumor necrosis factor-alpha on reversing hepatocellular carcinoma multidrug resistance in nude mouse MDR1 model of liver neoplasm.
    Ding L; Chen XP; Zhang ZW; Guan J; Zhang WG; Wang HP; Wang ZH; Li CL
    World J Gastroenterol; 2005 Sep; 11(36):5621-6. PubMed ID: 16237754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.